149 COMMONWEALTH DRIVE, MENLO PARK, CA
Termination of Distribution Services Agreement with Optime Care, Inc.
News
FDA Files New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Announces Second Quarter Financial Results and Provides Corporate Update
Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Announces First Quarter Financial Results and Provides Corporate Update
Met Primary Endpoint in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
SC TO-I
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-8 POS